To examine the effects of intravitreal ranibizumab ( Lucentis ; Genentech , Inc. , South San Francisco , CA ) treatment on patient-reported vision-related function , as assessed by 25-item National Eye Institute Visual Function Questionnaire ( NEI VFQ-25 ) scores , in patients with visual impairment secondary to center-involved diabetic macular edema ( DME ) .